News & Media

News Brief: Wex Pharmaceuticals Inc. Announces Authorization For The Conduct Of A Chemotherapy-induced Neuropathic Pain Clinical Trial In China, Singapore, Taiwan, Korea, Usa, And Canada

Vancouver, BC (November 30, 2022) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that it has received authorizations for its Phase 2B Clinical Trial Applications from the regulatory authorities of China, Singapore, Taiwan, Korea, USA, and Canada.

News Brief: Wex Pharmaceuticals Inc. Announces A Scientific Poster Presentation At The IASP World Congress On Pain On Its Lead Compound, Halneuron®

Vancouver, BC (September 22, 2022) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that a scientific poster on the Company’s lead drug candidate, Halneuron, was presented at the International Association for the Study of Pain (IASP) World Congress on

News Brief: Wex Pharmaceuticals Inc. Announces Abstract And Poster Presentation At The IASP World Congress On Pain On The Lead Compound, TTX (Halneuron )®

Vancouver, BC (August 31, 2022) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that a poster presentation on the Company’s lead drug candidate Halneuron was accepted for presentation at the International Association for the Study of Pain (IASP)

News Brief: Publication of Two Papers Using Halneuron®

Vancouver, BC (April 30, 2021) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for chronic pain, announced the publication of two clinical studies in a special issue of the Toxins Journal, Tetrodotoxin (TTX) as a Therapeutic Agent.